Document Detail

Quantitative loss of heterozygosity analysis for urothelial carcinoma detection and prognosis.
MedLine Citation:
PMID:  20206968     Owner:  NLM     Status:  MEDLINE    
OBJECTIVES: To evaluate loss of heterozygosity (LOH) using microsatellite polymorphism analysis as a diagnostic and prognostic marker at the time of transurethral resection and as a follow-up marker preceding cystoscopic evidence of recurrence compared with cytology. METHODS: A total of 127 urothelial carcinoma (UC) patients were included. Tumors were staged and graded according to the International Union Against Cancer-tumor, node, metastases system and to the 2004 World Health Organization classification. LOH urinalysis was performed using 8 markers and marker-specific LOH thresholds. Thirty control samples, obtained from healthy volunteers, were used to determine the positive cut-off for each marker. RESULTS: LOH was significantly more sensitive than cytology in low-grade (64.8% vs 38.5%, P <.001) and low-stage UC (68.6% vs 45.5%, P <.001). The cumulative sensitivity of cytology and LOH reached 74.7% (P <.001) for low-grade and 80.2% (P <.001) for low-stage tumors. Both urinary LOH at TP53 and chromosome 9p markers were associated with an increased risk of recurrence (relative risk = 1.73 [1.30-2.31], P = .0002) and occurred more frequently in the initial urine samples of patients who later relapsed from primary tumors (36.4% vs 0.0%, P <.05 and 57.6% vs 15.8%, P = .0001). Among 32 relapse patients, LOH was positive alongside cystoscopy in 25 of 32 cases and tested positive before cystoscopy detected recurrence in a further 5 of 25 cases. CONCLUSIONS: UC diagnosis and monitoring would greatly benefit from supplementing conventional cytology with LOH urinalysis, using a panel of 8 microsatellite markers with specific threshold levels. Given the limitations of both cystoscopy and cytology, novel molecular markers are needed for detection and follow-up of UC.
Delphine Collin-Chavagnac; Christophe Marçais; Stephane Billon; Françoise Descotes; Eric Piaton; Myriam Decaussin; Claire Rodriguez-Lafrasse; Alain Ruffion
Related Documents :
19620548 - An evaluation of 2537 gastrointestinal stromal tumors for a proposed clinical staging s...
3462898 - Malignancy grading of squamous cell carcinoma in the floor of the mouth related to clin...
16828848 - Testing of two binary grading systems for figo stage iii serous carcinoma of the ovary ...
11689578 - Does histologic grade have a role in the management of head and neck cancers?
500368 - Rhabdomyosarcoma of the head and neck: diagnosis and management.
22851568 - Induction chemotherapy and conformal radiation therapy for very young children with non...
Publication Detail:
Type:  Journal Article     Date:  2010-03-05
Journal Detail:
Title:  Urology     Volume:  76     ISSN:  1527-9995     ISO Abbreviation:  Urology     Publication Date:  2010 Aug 
Date Detail:
Created Date:  2010-08-10     Completed Date:  2010-09-13     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  0366151     Medline TA:  Urology     Country:  United States    
Other Details:
Languages:  eng     Pagination:  515.e1-7     Citation Subset:  IM    
Copyright Information:
Copyright 2010 Elsevier Inc. All rights reserved.
Service de Biochimie et Biologie Moléculaire Sud, Centre Hospitalier Universitaire Lyon Sud, Chemin du Grand Revoyet, Pierre Bénite, Hospices Civils de Lyon, France.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Aged, 80 and over
Carcinoma, Transitional Cell / genetics*
Loss of Heterozygosity*
Middle Aged
Prospective Studies
Sensitivity and Specificity
Urinary Bladder Neoplasms / genetics*

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Impact of Tadalafil Once Daily in Men With Erectile Dysfunction-Including a Report of the Partners' ...
Next Document:  Pelvic floor muscles and the external urethral sphincter have different responses to applied bladder...